Discover the best sectors for growth stocks in the next decade. Explore which sectors may present an opportunity to bolster ...

Hanmi and Eli Lilly began a development and marketing deal in 2015 for the drug. Lilly received worldwide rights to the molecule for all indications excluding China, Hong Kong, Taiwan, and Korea.

The Global Capability Centres wave is well underway in India, and the country has an opportunity to become a trusted partner ...

Renaissance Technologies took a new stake in Intel (NASDAQ:INTC), exited its position in Arm (NASDAQ:ARM), significantly upped its holdings in Nike (NYSE:NKE) and almost entirely sold out of Alphabet ...

For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025 ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

LLY PE Ratio (Forward) data by YCharts. Given the popularity of GLP-1 drugs and the potential for an oral GLP-1 drug launch in 2026, Lilly remains very well positioned. As such, I think the stock ...